ArticleBMC microbiology2026
Multidimensional characterization of a novel porcine Klebsiella pneumoniae phage Pkp-1.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification and Genomic Characterization of a Novel Teseptimavirus Species (vB_EcoP_S37A) and a Mosigvirus Phage (vB_EcoM_S37) Infecting Swine Extraintestinal PathogenicVeterinary sciences · 2026Article
- Molecular and biological characterization of a newly discovered Kayfunavirus bacteriophage targeting multidrug-resistant Escherichia coli from swine feces.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn recent years, the inappropriate use of antibiotics has led to the widespread emergence of multidrug-resistant Klebsiella pneumoniae (MDR-K. pneumoniae), resulting in infections that are increasingly challenging to manage clinically. Bacteriophages (phages) are emerging as promising alternatives to antibiotics. This study aimed to isolate and characterize lytic phages targeting MDR-K. pneumoniae, providing biological resources and experimental data for phage-based control of MDR-K. pneumoniae infections.
resultsA lytic phage, designated vB_KpnA_Pkp-1 (Pkp-1), was successfully isolated. TEM revealed that Pkp-1 belongs to the Caudoviricetes class, featuring an icosahedral head (62 ± 2 nm) and a short tail (17 ± 1 nm), with plaques displaying clear centers and translucent halos. Pkp-1 exhibited strict specificity for porcine-derived ST967 K. pneumoniae isolates. Its optimal MOI was 0.00001, with a latent period of 25 min and a burst size of 108 PFU/cell. Pkp-1 demonstrated high stability at 40 °C-60 °C and pH 4.0-11.0, effectively inhibiting planktonic bacteria and suppressing/eradicating biofilms. Genomic analysis revealed a 38,455 bp dsDNA genome with 48 open reading frames (ORFs), functions of 30 proteins were predicted (e.g., DNA polymerase, tail fiber), while the remaining 18 proteins were annotated as hypothetical. Genomic analysis confirmed the absence of virulence, lysogeny-related, and antibiotic resistance genes. Pkp-1 shared high identity with phages phi1_146013 (98.71%) and P7124 (97.25%). Recombination analysis revealed 19 recombination events, with two specifically located within the tail protein gene. Notably, this tail protein gene exhibits significant divergence from those of other classified Kayfunavirus phages.
conclusionThe lytic phage Pkp-1 represents a novel recombinant chimera within the Kayfunavirus genus, characterized by rapid replication, strict host specificity, environmental resilience, potent bactericidal activity, and biofilm clearance capability. The significant divergence of its tail protein from other Kayfunavirus phages suggests unique adaptive evolution. It represents a novel recombinant chimeric phage of the genus Kayfunavirus, with multiple recombination events in its genome. Its tail protein exhibits significant differences from those of other phages in the genus Kayfunavirus, indicating that it possesses adaptive evolutionary characteristics. These attributes position Pkp-1 as a potential biocontrol agent against MDR-K. pneumoniae infections, particularly in livestock and clinical settings. Further studies on in vivo efficacy and safety are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.